News

Launch of Global AMR R&D Hub in Geneve

7 June 2018

On the 22nd of May, alongside the annual World Health Assembly in Geneva the Global Antimicrobial Resistance and Development Hub (Global AMR R&D Hub) was launched.

Read more

Millions earmarked to boost research into new life-saving products to address the global rise of drug-resistant bacteria

7 June 2018

The UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Bill & Melinda Gates Foundation (BMGF) have joined the CARB-X partnership to support scientific research around the world to develop new vaccines, preventatives, and other products against drug-resistant bacterial infections, particularly among vulnerable populations in low- and middle-income countries.

Read more

Company in the spotlight: Avivia B.V.

19 April 2018

NADP supports R&D collaborations. To give further insights in companies active in this area, we have initiated the column “Company in the spotlight” issue. In our second edition, we speak with Dr. Hans Platteeuw, founder and CEO of Avivia B.V., a Nijmegen based company that supports pharmaceutical development for new and existing drugs including drug repurposing and reformulation.

Read more

Dutch researchers report on novel antimicrobial peptide to combat drug-resistant bacteria and biofilms

24 January 2018

Researchers from the Leiden University Medical Center (LUMC), Academic Medical Center (AMC) and the Association of Dutch Burn Centers have published on the use of antimicrobial peptide SAAP-148 to combat drug-resistant bacteria and biofilms in the latest edition of the scientific journal Science Translational Medicine.

Read more

Benefit Call open for Belgium-Netherlands Funding of International Trials

23 January 2018

The Belgian Health Care Knowledge Centre (KCE) and ZonMw, the Netherlands Organisation for Health Research and Care innovation, invest a maximum of 6 million euros in a joint programme under the name ‘BeNeFIT’.

Read more

Science and industry work together on affordable alternatives to antibiotics

19 December 2017

Almost fifty scientists and twenty companies will work on the development of new antibiotics and alternatives to antibiotics, which must become available for the healthcare system for a fair and affordable price. The research is done in eight projects that have received the green light from NWO Domain Applied and Engineering Sciences (AES). Together with the Ministry of Health, Welfare and Sport (VWS), NWO invests almost 7 million euros in the research programme.

Read more

Company in the spotlight: AGILeBiotics B.V.

14 December 2017

NADP supports R&D collaborations. To give further insights in companies active in this area, we have initiated the column“Company in the spotlight” issue. In this first edition, we speak with Dr. Andreas Bastian, the CEO of AGILeBiotics B.V. This antimicrobial developing company was founded earlier this year and is a perfect candidate to kick-off this topic!

Read more

Five projects awarded in NWO-CCC partnership program focusing on beneficial effects of carbohydrates

12 December 2017

The five awarded projects will investigate the beneficial effects of carbohydrates on microorganisms in the gastro-intestinal tract. The results are expected to aid in the reduction of antibiotics use in humans and farm animals. A total of 2.5 million Euros is invested in these projects, including contributions of TKI Agri&Food, Avebe, FrieslandCampina and NutritionSciences.

Read more

Ten projects awarded in 5th JPIAMR Joint Call

7 December 2017

The results of the 5th JPIAMR 2017 joint call for transnational research projects are presented. Within this funding opportunity over EUR 11.5 million have been awarded to 10 projects. Four of the supported projects have a Dutch coordinator.

Read more

Prof Marc Bonten announces clinical experiments in UMC Utrecht with bacteriophage therapy

22 November 2017

In a radio interview on 21st of November, Prof Marc Bonten, medical microbiologist, announced that the University Medical Centre in Utrecht (UMCU) is planning experimental treatments with bacteriophage therapy in lung infections. Prof Bonten expects the first experimental treatments with bacteriophage therapy to start in the first quarter of 2018, under the condition that the Medical Ethics Review Committee agrees with the investigation. Prof Marc Bonten is board member of the NADP.

Read more